Arlington Partners LLC Has $4.43 Million Stock Holdings in Johnson & Johnson $JNJ

Arlington Partners LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 11.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 29,010 shares of the company’s stock after purchasing an additional 2,882 shares during the period. Arlington Partners LLC’s holdings in Johnson & Johnson were worth $4,431,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. Brighton Jones LLC lifted its holdings in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Putney Financial Group LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $61,000. United Advisor Group LLC boosted its holdings in shares of Johnson & Johnson by 17.7% during the 4th quarter. United Advisor Group LLC now owns 6,547 shares of the company’s stock worth $947,000 after buying an additional 984 shares during the period. Armis Advisers LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at $742,000. Finally, Lakeshore Capital Group Inc. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $999,000. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Morgan Stanley boosted their target price on Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Royal Bank Of Canada upped their price target on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. Barclays upped their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $185.00 to $186.00 and gave the stock a “buy” rating in a report on Friday. Finally, Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $178.80.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Down 1.1%

Shares of NYSE JNJ opened at $174.22 on Tuesday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The business has a 50-day moving average of $173.14 and a 200-day moving average of $161.69. The firm has a market capitalization of $419.58 billion, a price-to-earnings ratio of 18.63, a PEG ratio of 2.24 and a beta of 0.40. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the business posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.